Apellis Pharmaceuticals, Inc. (APLS) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello, everyone, and welcome to the Q1 2025 Appellate Pharmaceuticals, Inc. Earnings Conference Call. At this time, all participants are in a listen-only mode. After the presentation, there will be a question and answer session. To participate, you will need to press star 11 on your telephone. You will then hear a message advising your hand is raised. To withdraw your question, simply press star 11 again. Please be advised that today's conference is being recorded. Now it's my pleasure to turn the call over to the Vice President of Communications, Tracey Veniz. The floor is yours. Good morning, and thank you for joining us to discuss Appellus' first quarter 2025 financial results. With me on the call, our co-founder and chief executive officer, Dr. Cedric Francois. Chief Financial Officer Tim Sullivan, Executive Vice President of Commercial David Acheson, and Chief Medical Officer Dr. Caroline Baumol is on the line for Q&A. Before we begin, let me point out that we will be making forward-looking statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and actual results may differ materially. I encourage you to consult the risk factors discussed in our SEC filings for additional detail. Now, I'll turn the call over to Cedric. Thank you, Tracy, and thank you all for joining us this morning. As many of you know, Apelids is a commercial stage biopharmaceutical company with two approved C3 targeting therapies, Cyfovri and Empaveli, and a growing pipeline of novel therapeutic compounds. Our focus is on addressing diseases with significant unmet need through targeted inhibition of the complement system. The first quarter of 2025 presented a combination of challenges and progress. Despite growth in i...